Hostname: page-component-78c5997874-94fs2 Total loading time: 0 Render date: 2024-11-02T19:53:48.110Z Has data issue: false hasContentIssue false
  • English
  • Français

A double-blind, placebo controlled, crossover trial of carbamazepine in overactive, severely mentally handicapped patients

Published online by Cambridge University Press:  09 July 2009

Andrew H. Reid ,
Graham J. Naylor  and
David S. G. Kay
Andrew H. Reid*
Affiliation:
Dundee Psychiatric Service, Strathmartine Hospital, by Dundee; and the University Department of Psychiatry, Ninewells Hospital and Medical School, Dundee
Graham J. Naylor
Affiliation:
Dundee Psychiatric Service, Strathmartine Hospital, by Dundee; and the University Department of Psychiatry, Ninewells Hospital and Medical School, Dundee
David S. G. Kay
Affiliation:
Dundee Psychiatric Service, Strathmartine Hospital, by Dundee; and the University Department of Psychiatry, Ninewells Hospital and Medical School, Dundee
*
1Address for correspondence: Dr A. H. Reid, Strathmartine Hospital, by Dundee DD3 OPG.
Get access Rights & Permissions [Opens in a new window]

Synopsis

A double-blind, placebo controlled, crossover trial of carbamazepine in 12 severely and profoundly mentally retarded, overactive adult patients is described. The trial lasted 7 months and those patients in whom overactivity was the dominant problem responded to some degree to carbamazepine with a reduction in overactivity. This was particularly so in patients in whom overactivity was accompanied by some elevation of mood. Patients in whom overactivity was part of a wider spectrum of multiple behaviour disorders showed a scatter of responses. There was no relationship between response to carbamazepine and the presence or absence of epilepsy. The trial identified a small group of mentally retarded patients in whom carbamazepine might be clinically useful.

Type
Research Article
Information
Psychological Medicine , Volume 11 , Issue 1 , February 1981 , pp. 109 - 113
Copyright
Copyright © Cambridge University Press 1981

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

Al-Kaisi, A. H. & McGuire, R. J. (1974). The effect of sulthiame on disturbed behaviour in mentally subnormal patients. British Journal of Psychiatry 124, 45–49.CrossRefGoogle ScholarPubMed
Crome, L. & Stern, J. (1972). Pathology of Mental Retardation. Churchill Livingstone: London.Google ScholarPubMed
Hughes, P. S. (1977). Survey of medication in a subnormality hospital. British Journal of Mental Subnormality 23, 88–94.CrossRefGoogle Scholar
James, F. E. & Snaith, R. P. (1979). Psychiatric Illness and Mental Handicap. Gaskell Press: London.Google Scholar
Kanjilal, G. C. (1977). An evaluation of tegretol in adults with epilepsy.In Tegretol in Epilepsy: Proceedings of an International Meeting (ed. Roberts, F. D.), pp. 55–57. Geigy Pharmaceuticals.Google Scholar
Kirman, B. (1975). Drug therapy in mental handicap. British Journal of Psychiatry 127, 545–549.Google Scholar
Ounsted, C., Lindsay, J. & Norman, R. (1966). Biological Factors in Temporal Lobe Epilepsy. Clinics in Developmental Medicine, 22. Spastics Society Medical Education and Information Unit. Heinemann Medical: London.Google Scholar
Reid, A. H. (1979). Clinical features of psychotic illness in adult mental defectives. In Psychiatric Illness and Mental Handicap (ed. James, F. E. and Snaith, R. P.), pp. 81–90. Gaskell Press: London.Google Scholar
Reid, A. H., Ballinger, B. R. & Heather, B. B. (1978). Behavioural syndromes identified by cluster analysis in a sample of 100 severely and profoundly retarded adults. Psychological Medicine 8, 399–412.Google Scholar